Security
HOWL · Werewolf Therapeutics, Inc.
HOWLNASDAQCommon stockCurrentCIK 1785530Updated Sep 26, 2026
HOWL price & chart
Loading TradingView…
NASDAQ:HOWL on TradingView ↗About the company
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has leveraged its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics’ most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.
In the news
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement ↗
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement ↗
Ra Capital sells $253,568 in Werewolf Therapeutics (NASDAQ:HOWL) stock ↗
Recent filings
S-4 filing
425 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 69,396,000Source | 126,929,000Source | 174,833,000Source | 160,245,000Source |
| Property, Plant and Equipment, NetUSD | 4,688,000Source | 6,322,000Source | 7,958,000Source | 8,988,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 57,050,000Source | 110,995,000Source | 134,343,000Source | 129,315,000Source |
| Assets, CurrentUSD | 58,586,000Source | 113,066,000Source | 138,370,000Source | 140,200,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,536,000Source | 2,071,000Source | 2,677,000Source | 3,957,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,216,000Source | 6,001,000Source | 6,888,000Source | 8,463,000Source |
| Other Assets, NoncurrentUSD | 5,000Source | 320,000Source | 594,000Source | 1,380,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 44,591,000Source | 53,539,000Source | 63,459,000Source | 37,908,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 500,210,000Source | 487,973,000Source | 455,443,000Source | 429,039,000Source |
| Retained Earnings (Accumulated Deficit)USD | -475,410,000Source | -414,588,000Source | -344,073,000Source | -306,705,000Source |
| Stockholders' Equity Attributable to ParentUSD | 24,805,000Source | 73,390,000Source | 111,374,000Source | 122,337,000Source |
| Liabilities and EquityUSD | 69,396,000Source | 126,929,000Source | 174,833,000Source | 160,245,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 36,148,000Source | 15,180,000Source | 19,378,000Source | 23,989,000Source |
| Operating Lease, Liability, CurrentUSD | 1,751,000Source | 1,557,000Source | 1,608,000Source | 2,084,000Source |
| Accounts Payable, CurrentUSD | 754,000Source | 3,035,000Source | 1,336,000Source | 1,221,000Source |
| Operating Lease, Liability, NoncurrentUSD | 7,684,000Source | 9,435,000Source | 10,992,000Source | 12,600,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 191,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,407,000Source | 10,588,000Source | 8,860,000Source | 14,152,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term DebtUSD | 32,085,000Source | 32,085,000Source | 40,000,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,245,000Source | 8,826,000Source | 8,008,000Source | 7,400,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -60,292,000Source | -56,188,000Source | -32,612,000Source | -40,596,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | -254,000Source | -769,000Source | -3,611,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 254,000Source | 769,000Source | 3,611,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,028,000Source | 13,080,000Source | 58,429,000Source | 15,906,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -54,264,000Source | -43,362,000Source | 25,048,000Source | -28,301,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 57,951,000Source | 112,215,000Source | 155,577,000Source | 130,529,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,133,000Source | 3,358,000Source | 2,556,000Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | 6,245,000Source | 8,826,000Source | 8,008,000Source | 7,400,000Source |
| Amortization of Debt Issuance CostsUSD | — | 0Source | 60,000Source | 203,000Source |
| DepreciationUSD | 1,634,000Source | 1,814,000Source | 1,764,000Source | 1,104,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 2,070,000Source | 1,621,000Source | — | — |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -7,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -553,000Source | — | — |
| General and Administrative ExpenseUSD | 15,847,000Source | 19,045,000Source | 18,670,000Source | 18,696,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 5,274,000Source | 4,656,000Source | — | — |
| Investment Income, InterestUSD | 3,108,000Source | 6,673,000Source | 7,416,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -60,822,000Source | -70,515,000Source | -37,368,000Source | -53,810,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -60,822,000Source | -70,515,000Source | — | -53,810,000Source |
| Nonoperating Income (Expense)USD | -145,000Source | 3,079,000Source | 3,135,000Source | 2,246,000Source |
| Operating ExpensesUSD | 60,677,000Source | 75,479,000Source | 60,446,000Source | 72,457,000Source |
| Other Nonoperating Income (Expense)USD | 2,021,000Source | 1,615,000Source | -1,142,000Source | — |
| Payments of Financing CostsUSD | — | — | 0Source | 88,000Source |
| Proceeds from Issuance of Common StockUSD | 5,939,000Source | 23,576,000Source | 18,329,000Source | 16,191,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 35,000Source | 7,000Source | 254,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -60,677,000Source | -73,594,000Source | -40,503,000Source | -56,056,000Source |
| Other Nonoperating Income (Expense)USD | 2,021,000Source | 1,615,000Source | -1,142,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -60,822,000Source | -70,515,000Source | -37,368,000Source | -53,810,000Source |
| Earnings Per Share, BasicUSD per share | -1.32Source | -1.63Source | -1.05Source | -1.86Source |
| Earnings Per Share, DilutedUSD per share | -1.33Source | -1.63Source | -1.05Source | -1.86Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 46,018,888Source | 43,332,088Source | 35,646,572Source | 28,864,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 46,810,252Source | 43,859,664Source | 35,646,572Source | 28,864,000Source |
| Interest Expense (non-operating)USD | 5,274,000Source | 4,656,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 15,847,000Source | 19,045,000Source | 18,670,000Source | 18,696,000Source |
| Interest ExpenseUSD | — | — | 3,139,000Source | — |
| Interest Expense, DebtUSD | 5,274,000Source | 3,311,000Source | — | — |
| Investment Income, InterestUSD | 3,108,000Source | 6,673,000Source | 7,416,000Source | — |
| Investment Income, NetUSD | — | — | — | 1,908,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -60,822,000Source | -70,515,000Source | — | -53,810,000Source |
| Nonoperating Income (Expense)USD | -145,000Source | 3,079,000Source | 3,135,000Source | 2,246,000Source |
| Operating ExpensesUSD | 60,677,000Source | 75,479,000Source | 60,446,000Source | 72,457,000Source |
| Research and Development ExpenseUSD | 44,830,000Source | 56,434,000Source | 41,776,000Source | 53,761,000Source |
Offerings
Registration 333-299079
Filing attachments
ny20081588x1_ex107.htm · S-4 · 2026-09-22
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Werewolf Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registe…
Read attachment ↗ny20081588x1_ex99-1.htm · S-4 · 2026-09-22
Exhibit 99.1 CONSENT OF PIPER SANDLER & CO. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Werewolf Therapeutics, Inc. (the “Company”) as an Annex to the Proxy Statement/Prospectus relating to the proposed merger of the Company with Ambros Therapeutics, Inc. contained in the Registration Statement on Form S-4, as filed with the Securities and Exchange Commission, and to references to such opinion and the quotation or summarization of such opinion in such …
Read attachment ↗ny20081588x1_ex99-2.htm · S-4 · 2026-09-22
Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Werewolf Therapeutics, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Werewolf Therapeutics, Inc. following the consummation of the merger in the R…
Read attachment ↗d102535dex41.htm · 8-K · 2026-08-21
EX-4.1 3 d102535dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗d102535dex42.htm · 8-K · 2026-08-21
EX-4.2 4 d102535dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 FORM OF MERGER PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [•], 202[•] Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is entitled, subject to the terms set fo…
Read attachment ↗d102535dex991.htm · 8-K · 2026-08-21
EX-99.1 11 d102535dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy Pivotal CRPS-RISE Phase …
Read attachment ↗